Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study. Issue 5 (1st August 2022)

• Record Type: Journal Article
• Authors: Deodhar, Atul A.; Shiff, Natalie J.; Gong, Cinty; Hsia, Elizabeth C.; Lo, Kim Hung; Kim, Lilliane; Xu, Stephen; Reveille, John D.
• Is Part Of: Journal of clinical rheumatology. Volume 28:Issue 5(2022)
• Page Start: 270
• Page End: 277
• Publication Date: 2022-08-01
• Subjects: ankylosing spondylitis -- efficacy -- inflammatory back pain -- intravenous golimumab -- safety -- tumor necrosis factor inhibitor; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001853
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Background/Objective: This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). Methods: The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab 2 mg/kg at weeks 0 and 4 and then every 8 weeks through week 52, or placebo at weeks 0, 4, and 12 with crossover to IV golimumab at week 16. Clinical efficacy was assessed by ≥20% improvement in Assessment of Spondyloarthritis International Society response criteria (ASAS20), ≥50% improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50), and Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (inactive disease). Using self-reported duration of inflammatory back pain (IBP), patients were grouped into quartiles: first = ED and fourth = LD. Descriptive statistics summarized efficacy and safety findings through 1 year. Results: Early disease patients (n = 60) were ~10 years younger and had shorter median AS (IBP) symptom duration (2–3 years) versus LD patients (n = 52; 21–24 years). At week 16, numerically higher proportions of golimumab- than placebo-treated patients achieved ASAS20 (ED: 71% vs. 32%; LD: 67% vs. 21%), BASDAI 50 (ED: 40% vs. 12%; LD: 33% vs. 7%), and ASDAS <1.3 (ED: 17% vs. 4%; LD 8% vs. 0%) regardless of IBP duration. Efficacy was durable through 1 year of treatment; however, response rates were numerically higher in patients with ED versus LD. Through week 60, adverse events and serious adverse events, respectively, were reported by 46% and 3% of ED patients and 61% and 2% of LD patients. Conclusion: Prompt diagnosis of AS and early treatment with IV golimumab may yield more robust improvements in disease activity.